RxDoctor Payments Data

Roger Erro, MD

Psychosomatic Medicine · Philadelphia, PANPI 1518185453

Payments from drug & device makers

$2,105in general payments, 2019–2025

Across 84 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
  • Vanda Pharmaceuticals Inc.$396
  • Alkermes, Inc.$313
  • Sunovion Pharmaceuticals Inc.$254
  • Johnson & Johnson$144
  • Almatica Pharma LLC$125
  • plus $167 from 3 others

What the payments were for

  • Food & beverage$2,07499%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychosomatic medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,293
Medicare patients
68
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl19$6,146
Mirtazapine47$1,410
Alprazolam365$1,332
Aripiprazole22$863
Trazodone Hcl157$841
Ziprasidone Hcl24$840
Quetiapine Fumarate79$497
Duloxetine Hcl49$462
Ramelteon13$420
Bupropion XlBupropion Hcl44$404
Escitalopram Oxalate41$279
Hydroxyzine Pamoate30$265
Lorazepam92$244
Fluoxetine Hcl49$243
Hydroxyzine Hcl19$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$125$10555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other psychosomatic medicine in Philadelphia

Where these figures come from

Is this you, or does something look wrong? →